Zymeworks stock has seen its consensus analyst price target rise from $21.45 to $23.68 per share, signaling renewed optimism among market watchers. Although forecasts for revenue growth have become more conservative, the company’s progress on its therapeutic pipeline and upcoming clinical milestones are energizing bullish sentiment. Stay tuned to discover how you can continue tracking shifts in analyst outlooks and the evolving narrative for Zymeworks moving forward.

🐂 Bullish Takeaways

• B. Riley has initiated coverage of Zymeworks with a Buy rating and set an ambitious $30 price target, referencing the company’s portfolio of “highly differentiated” and “clinically de-risked” therapies.

• The firm is optimistic about the potential for Zymeworks’ Ziihhera program, seeing an expansion into gastric and breast cancer as a key growth area.

• B. Riley highlights the upcoming Jazz Pharmaceuticals Phase 3 HERIZON-GEA readout as a potential catalyst for positive estimate revisions.

• Citi raised its price target on Zymeworks to $22 from $19, maintaining a Buy rating and citing increasing momentum for Zanidatamab in biliary tract cancer.

• Both firms note the promising clinical pipeline and the impact of upcoming data releases as drivers for positive sentiment and valuation upside.

🐻 Bearish Takeaways

• While recent commentary from B. Riley and Citi has been predominantly positive, analysts caution that valuation assumptions depend on successful clinical milestones being met in the near term.

• There is some acknowledgement that much of the medium-term upside may already be reflected in the current price targets. This moderates expectations for outsized gains unless new data materially exceeds consensus forecasts.

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there’s more to the story. Head to the Simply Wall St Community to discover more perspectives or begin writing your own Narrative!

• Zymeworks announced that preliminary Phase 1 results of its antibody-drug conjugate ZW191, which targets folate receptor proteins found in most high-grade serous ovarian and lung adenocarcinomas, will be presented at the AACR, NCI, and EORTC Conference in October 2025.

• The company has voluntarily discontinued clinical development of ZW171, a T cell engager targeting various cancer types, due to safety concerns and insufficient benefit. Participants will remain in safety follow-up as planned.

• Zanidatamab, Zymeworks’ dual HER2-targeted bispecific antibody, received global regulatory approvals, including in the U.S., Europe, and China, for use in patients with previously treated, unresectable or metastatic HER2-positive biliary tract cancer.

• The U.S. FDA has cleared an investigational new drug application for ZW251, a glypican-3 (GPC3) targeted antibody-drug conjugate for liver cancer. This paves the way for clinical trials to commence in 2025.